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Telomeres, the protectiveDNA-protein complexes at the ends of linear chromosomes, are important for genome stability. Leukocyte
or peripheral blood mononuclear cell (PBMC) telomere length is a potential biomarker for human aging that integrates genetic,
environmental, and lifestyle factors and is associated withmortality and risks formajor diseases. However, only a limited number of
studies have examined longitudinal changes of telomere length and few have reported data on sorted circulating immune cells. We
examined the average telomere length (TL) in CD4+, CD8+CD28+, and CD8+CD28−T cells, B cells, and PBMCs, cross-sectionally
and longitudinally, in a cohort of premenopausal women. We report that TL changes over 18 months were correlated among these
three T cell types within the same participant. Additionally, PBMCTL change was also correlated with those of all three T cell types,
and B cells. The rate of shortening for B cells was significantly greater than for the three T cell types. CD8+CD28− cells, despite
having the shortest TL, showed significantly more rapid attrition when compared to CD8+CD28+ T cells. These results suggest
systematically coordinated, yet cell type-specific responses to factors and pathways contribute to telomere length regulation.
1. Introduction
Telomeres are theDNA-protein complexes at the end of linear
chromosomes that are important for genome stability and
integrity [1]. The attrition of telomeric DNA can be counter-
acted by the action of telomerase [2]. Telomere shortening is
a manifestation of progression toward cellular damage that
can contribute to organismal aging [3]. Human leukocyte
telomere length decreases as people age [4] and is determined
by multiple inputs including genetic, environmental, and
lifestyle factors and disease status [5, 6]. Telomere length is
cross-sectionally associated with or predictive of early onset
of several chronic diseases [7–11]. The cellular signals and
pathways that determine telomere length changes are largely
unknown, but several have been proposed. Telomerase, the
enzyme that extends telomeric DNA, preferentially acts on
short telomeres [12] in cultured cells. In several clinical
studies, high telomerase in unstimulated PBMC in combina-
tion with short telomere length [13–18] is cross-sectionally
associated with worse outcomes, which has led to the yet
untested possibility that telomerase may be elevated as a
compensatory mechanism in response to short telomeres.
An important question in the field of immune cell
telomere research is to understand the extent to which
systemic factors may contribute to TL shortening affecting
many immune cell subsets, or whether TL shortening rates
need to be evaluated separately for each cell subset. If cell-
specific TL shortening predominates, this would shift the
emphasis away from common upstream factors and toward
cell-specific metrics and pathways.
In fetuses and newborn children [20–25], telomere
lengths are similar in different tissues, whereas, in adults,
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different tissues exhibit more marked differences in telomere
length [19, 23, 25]. These differences likely result from dif-
ferent replication histories, cell type-specific regulatory path-
ways, and microenvironments in which the cells reside. Lin
et al. [26] recently reported that although telomere lengths
were correlated within an individual among PBMCs, T cells
and B cells, and monocytes, the rates of change of telomere
length for PBMCs, T cells, B cells, and monocytes were
not correlated. Telomerase activity, changes of lymphocyte
composition, and physiological conditions such as elevated
blood glucose and IL-6 levels explained most of the age-
dependent telomere length attrition, which is 30% of the total
telomere attrition variability.
Comparison of TL in different immune cell types in a
cohort of postmenopausal women shows that, relative to
other circulating immune cell subtypes, B cells have longer
telomeres. TL is especially shortened in CD8+CD28− T
cells, compared to other T cell types [19]. These senescent
memory cells exert negative effects on immune function
[27]. However, whether or not longitudinal telomere length
changes in these various immune cell types are correlated has
not been studied. Information on the longitudinal TL change
in these related but distinct immune cell types will shed light
on systemic versus cell type-specific telomere regulation and
may help identify the most vulnerable immune cell subsets.
2. Materials and Methods
2.1. Description of the Cohorts. The entire cohort consists
of 183 healthy San Francisco Bay Area premenopausal
women who were caregiving for their biological child with
an autism spectrum disorder (high stress) and matched
control women (low stress), who had children free of any
diagnoses. The UCSF Institutional Review Board for Human
Research approved the study and all participants provided
written consent for this study. All 183 participants had
peripheral blood mononuclear cells (PBMCs) sorted into
CD4+, CD8+CD28+, and CD8+CD28− T cells and B cells
at baseline. In addition, 39 participants (20 high stress and
19 low stress based on being the first participants recruited
into the study group) were selected to have PBMC sorted
into CD4+, CD8+CD28+, and CD8+CD28− T cells and B
cells at 18-month follow-up. Analyses by levels of chronic
stress are beyond the scope of this paper and will be reported
elsewhere. Caregivers and controls did not differ significantly
in age [controls:mean (SD)=41.5 (4.5), caregivers:mean (SD)
= 42.3 (5.6), df = 181, 𝑡 = −0.987, and 𝑝 = 0.325] or BMI
[controls: mean (SD) = 25.1 (4.7), caregivers: mean (SD) =
25.9 (5.7), df = 179, 𝑡 = −1.016, and 𝑝 = 0.311]. The sample
was examined as a whole, since the questions addressed here
were independent of age and stress level. The sample was
mostlywhite, with amean age of 41.9 (range: 24–51) andmean
BMI of 25.5 (range: 17.2–45.1) and had completed college
(Table 1).
2.2. Telomere Length Assay. Peripheral blood mononuclear
cells were purified by Ficoll gradient and sorted into CD4+,
CD8+CD28+, and CD8+CD28− T cells and B cells as
Table 1: Participant demographics from the current study∗.
Characteristic Mean (SD)/%
Age 41.9 (5.1)
BMI (kg/m2) 25.5 (5.2)
Education, years 16.9 (2.1)
Income ($1,000) 142.2 (53.4)
Race/ethnicity (%)
Caucasian 77.6
Black 3.3
Hispanic or Latina 7.7
Asian, Pacific Islander, or Native American 10.8
aThe number of participants ranges from 179 to 183.
described earlier [19]. Sorted cells were stored as dry pellets
at −80∘C and total genomic DNA was purified using the
QIAamp® DNA Mini kit (QIAGEN, Hilden, Germany; Cat.
number 51104) in batches. DNAwas stored at−80∘C for batch
telomere length measurement. DNA was extracted within 6
months prior to the assay time.
The telomere length assay is adapted from the published
original method by Cawthon [19, 28]. The telomere thermal
cycling profile consists of cycling for T (telomeric) PCR:
96∘C for 1 minute, denaturing at 96∘C for 1 second, and
annealing/extending at 54∘C for 60 seconds, with fluores-
cence data collection, 30 cycles; cycling for S (single-copy
gene) PCR: 96∘C for 1 minute, denaturing at 95∘C for 15
seconds, annealing at 58∘C for 1 second, and extending at 72∘C
for 20 seconds, 8 cycles; followed by denaturing at 96∘C for
1 second, annealing at 58∘C for 1 second, extending at 72∘C
for 20 seconds, and holding at 83∘C for 5 seconds with data
collection, 35 cycles.
The primers for the telomere PCR are tel1b [5󸀠-
CGGTTT(GTTTGG)
5
GTT-3󸀠], used at a final concentration
of 100 nM, and tel2b [5󸀠-GGCTTG(CCTTAC)
5
CCT-3󸀠],
used at a final concentration of 900 nM. The primers
for the single-copy gene (human beta-globin) PCR are
hbg1 [5󸀠-GCTTCTGACACAACTGTGTTCACTAGC-3󸀠],
used at a final concentration of 300 nM, and hbg2 [5󸀠-
CACCAACTTCATCCACGTTCACC-3󸀠], used at a final
concentration of 700 nM. The final reaction mix contains
20mM Tris-HCl, pH 8.4; 50mM KCl; 200𝜇M each dNTP;
1% DMSO; 0.4x Syber Green I; 22 ng E. coli DNA; 0.4 units
of platinum Taq DNA polymerase (Invitrogen Inc.); and 2–
10 ng of genomic DNA in a 11 𝜇L reaction. Tubes containing
26, 8.75, 2.9, 0.97, 0.324, and 0.108 ng of a reference DNA
(fromHela cancer cells) are included in each PCR run so that
the quantity of targeted templates in each research sample
can be determined relative to the reference DNA sample by
the standard curve method. The same reference DNA was
used for all PCR runs.
To control for interassay variability, 8 control DNA
samples are included in each run. In each batch, the T/S ratio
of each control DNA is divided by the average T/S for the
same DNA from 10 runs to get a normalizing factor. This is
done for all 8 samples and the average normalizing factor for
all 8 samples is used to correct the participant DNA samples
to get the final T/S ratio. The T/S ratio for each sample was
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measured twice. When the duplicate T/S value and the initial
value vary by more than 7%, the sample was run the third
time and the two closest values were reported. The average
coefficient of variation (CV) of this study is 2.3% (±1.8%).
To convert the T/S ratios to base-pairs, the T/S ratios of
a set of genomic DNA samples from the human fibroblast
primary cell line IMR90 at different population doublings,
as well as with the telomerase protein subunit gene (hTERT)
transfected into a lentiviral construct, were determined. The
mean TRF length from these DNA samples was measured
using Southern blot analysis, and the slope of the plot of
mean TRF length versus T/S for these samples served as the
conversion factor for calculation of telomere length in base-
pairs from the T/S ratio. The equation for conversion from
T/S ratio to base-pairs is base-pairs = 3274 + 2413 ∗ (T/S).
2.3. Telomerase Activity Assay. Gel-TRAP assays were per-
formed by the Telomerase Repeat Amplification Protocol
(TRAP) using a commercial kit (TRAPeze TelomeraseDetec-
tion Kit, Millipore) with modifications [19, 28]. Peripheral
blood mononuclear cells were purified by Ficoll gradient and
then sorted into CD4+, CD8+CD28+, and CD8+CD28− T
cells and B cells as described earlier [19]. 5 × 105–1 × 106 cells
per sample were pelleted and stored as dry pellets at −80∘C.
Cell pellets were lysed with 1XCHAPS buffer as directed by
the manual for the TRAPeze kit. An extract corresponding
to 5000 cells/𝜇L was made and stored at −80∘C and assayed
in batches. All the cell subtypes from the same individual
were assayed in the same batch. The reaction was carried
out according to the TRAPeze kit manual and run on an
8% polyacrylamide-8M urea sequencing gel. The gel was
exposed to a phosphorimager plate overnight and scanned on
a Typhoon 8600 Imager (GEHealthcare, Piscataway, NJ).The
293T cancer cell line was used as a positive telomerase activity
control and standard. Telomerase activity was expressed as
equivalent of number of 293T cells. Telomerase activity was
quantified using the software ImageQuant 5.2 (GE Health-
care, Piscataway,NJ). Briefly, signals from the product ladders
on the gels were added and normalized against the signal
from the internal control band for the same lane to get the
product/internal control value. For each telomerase activity
assay reaction, the product/internal value was divided by
the product/internal control value from twenty 293T cells
and then multiplied by 20 to obtain the final telomerase
activity units, defined as 1 unit = the amount of product from
one 293T cell/10,000 immune cells. The average intra-assay
variability of PBMC samples (𝑁 = 6, assayed in triplicate)
was 8% and the interassay variability of PBMC samples (𝑁 =
24, assayed on 2 different days) was 6.7%.
2.4. Statistical Analysis. All analyses of TL and TL change
were performed on the sample providing both baseline and
follow-up data (𝑁 = 39). Data were complete across all
cell types at both baseline and follow-up. Examination of
TL distributions within cell types revealed skewness greater
than ±1; subsequently, all data were natural log-transformed
providing skewness less than 1. No outliers beyond ±4
standard deviations were observed; thus, all values were
retained for analysis.
Partial correlations were used to examine cross-
sectional relations in TL among CD4+, CD8+CD28+, and
CD8+CD28− T cells and B cells, separately, for baseline and
follow-up data.
Next, analysis of TL at baseline with TL change (cal-
culated as TL at baseline subtracted from TL at follow-up)
revealed significant relations between baseline and shorten-
ing. Thus, following Verhulst et al. [29], adjusted TL change
values were calculated to correct for apparent regression-to-
the-mean (RTM). Finally, the extent of TL change among cell
types was compared using a series of paired 𝑡-tests for each
combination of cell types. A Bonferroni correction was used
to adjust for these multiple comparisons.
3. Results and Discussions
3.1. Assay Considerations for Longitudinal Telomere Length
Measurement. On average, telomere length changes over
time are relatively small [4]. This poses a special challenge
for longitudinal measurements, as apparent changes could
be attributed to either assay variation or real changes, or
a combination of both. We took special precautions to
implement the following assay design in order to rule out
potential batch differences that might confound longitudinal
comparison. The assay was performed as batches of maximal
96 samples on a 384-well assay plate, with triplicate well
for each sample. DNA samples from PBMC and sorted
cells of the same participant for both the baseline and 18-
month follow-up visits were always assayed in the same 96-
sample batch. This ensured that comparisons of baseline
and 18-month data were always within the same batch, thus
eliminating possible systematic biases due to batch difference.
In addition, we used one single lot for each reagent for the
entire study to eliminate possible batch difference due to
different reagent lots.
3.2. Telomere Length Change in Sorted Lymphocyte Subtypes
within Each Subject Is Correlated. Earlier work by our group
showed that telomere length of total PBMCs and sorted
CD4+, CD8+CD28+, and CD8+CD28− T cells and B cells of
each subject were correlated. This finding, made in a cohort
of postmenopausal women (average age ± SD = 61 ± 8.3)
[19], was replicated in the current cohort of premenopausal
women. We found that telomere length measurements of
CD4+, CD8+CD28+, and CD8+CD28− T cell and B cell
populationswithin each subject were correlated andwere also
significantly correlated with PBMC telomere length for both
baseline and 18-month follow-up visits with the exception
of CD8+CD28+ and CD8+CD28− cells at baseline visit
(Figure 1(a), Tables 2 and 3); Tables S1 and S2 show column
statistics (see Supplementary Material available online at
http://dx.doi.org/10.1155/2016/5371050). Also, consistent with
earlier results, we found that, of the 5 types examined,
B cells exhibited the longest mean telomere length, while
CD8+CD28− T cells had the shortest mean telomere length
(Figure 1(b) and Table S3).
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Figure 1: Telomere length in sorted cells and PBMCs. Box and whisker plots display interquartile range, median values, and maximum and
minimum values. Telomere length is expressed as basepairs as described earlier [19]. (a) Telomere length in B cells, CD4+, CD8+CD28+,
and CD8+CD28− T cells, and PBMCs at base visit and 18 month visit. (b) Telomere length of the base visit and that of 18-month visit from
the same cell type of the same individual are highly correlated. The graph includes telomere length from PBMC, CD4+, CD8+CD28+, and
CD8+CD28− T cells and B cells from 39 subjects. (c) Telomere length change from base visit to 18 months is negatively correlated with
telomere length at base visit. (d) Telomere length change from base visit to 18 months in total PBMC, CD4+, CD8+CD28+, and CD8+CD28−
T cells and B cells.𝑁 = 39 for each cell type.
Multiple previous reports of longitudinal changes in
mean telomere length showed a baseline effect, where change
in telomere length was negatively correlated with the baseline
measurement [30–38]. This phenomenon was also observed
for each cell subtype in our cohort, with the correlation
in B, CD8+CD28+, and PBMC cells reaching statistical
significance (Table S4). One possible explanation of this
baseline effect is proposed by Verhulst et al. as regression to
themean due to assay error [29]. To address this, we analyzed
the telomere length data after correction for regression to
the mean using a regression-to-the-mean (RTM) adjustment
approach proposed by Verhulst et al. [29]. The baseline
effect disappeared after the adjustment indicating that RTM
contributed to the baseline effect observed in this data set
(Table S4). We therefore analyzed the telomere length data
both as unadjusted and RTM-adjusted.
Cross-sectionally, at both baseline and at 18M, telomere
lengths of all the cell types from the same subject were
Journal of Immunology Research 5
Table 2: Correlation of telomere length among different cell types at the base visit (𝑁 = 39).
𝑟 (Pearson) B CD8+CD28− CD8+CD28+ CD4+ PBMC
B — 0.414∗∗ 0.492∗∗ 0.614∗∗∗∗ 0.544∗∗∗
CD8+CD28− — 0.074 0.322∗ 0.336∗
CD8+CD28+ — 0.796∗∗∗∗ 0.572∗∗∗
CD4+ — 0.834∗∗∗∗
∗∗∗∗
𝑝 < 0.0001.
∗∗∗
𝑝 < 0.001.
∗∗
𝑝 < 0.01.
∗
𝑝 < 0.05.
T/S ratios were natural log-transformed and adjusted for age.
Table 3: Correlation of telomere length among different cell types at the 18-month visit (𝑁 = 39).
𝑟 (Pearson) B CD8+CD28− CD8+CD28+ CD4+ PBMC
B — 0.416∗∗ 0.683∗∗∗∗ 0.723∗∗∗∗ 0.713∗∗∗∗
CD8+CD28− — 0.500∗∗ 0.401∗∗ 0.436∗∗∗
CD8+CD28+ — 0.868∗∗∗∗ 0.753∗∗∗∗
CD4+ — 0.785∗∗∗∗
∗∗∗∗
𝑝 < 0.0001.
∗∗∗
𝑝 < 0.001.
∗∗
𝑝 < 0.01.
∗
𝑝 < 0.05.
T/S ratios were natural log-transformed and adjusted for age.
strongly correlated with the exception of CD8+CD28+ and
CD8+CD28− cells at baseline visit (Figure 1(b), Table S5).
Interestingly, we found that telomere length changes were
also correlated within the same subject. In the RTM-adjusted
analysis, within the T cell subtypes, changes of TL in CD4+,
CD8+CD28+, and CD8+CD28− were all correlated. In con-
trast, TL change in B cells was not correlated with the three
T cell subtypes. TL change in PBMC was correlated with the
three T cell types as well as B cells (Table 4). The unadjusted
analysis shows a similar pattern, except that the correlation
of PBMC with CD8+CD28+, CD8+CD28−, and B cells does
not reach statistical significance (Table S6). This finding is
consistent with the lineage relationships among these cell
types: the three T cell types are more closely related with
each other during cell differentiation than B cells. As PBMCs
contain T cells and B cells, the correlation of PBMC TL
change with the three T cell types and with B cells as well
appears to reflect this composition of PBMCs.
3.3. Telomere Length Decreases More in B Cells and
CD8+CD28− Cells. Overall, telomere length decreased over
the 18-month period, as expected (Figure 1(d), Table 5).
However, the rate of change differed for different cell types.
B cells decreased most (at an average rate of 196 bp per year)
and CD8+CD28− telomere length declined the second fastest
(90 bp per year). After RTM adjustment, these differences
in the rates of telomere length change persisted and even
appeared to be slightly stronger: B cells had more telomere
attrition compared to CD8+CD28+, CD4+, and PBMC cells
(Table 6). Interestingly, although CD28+CD28− cells have
shorter telomeres compared to CD8+CD28+ cells, they
have a higher attrition rate compared to CD8+CD28+ cells.
CD8+CD28− cells have a higher attrition rate compared
to CD4, CD8+28+, and PBMCs but this was marginally
significant after adjustments for multiple comparisons. This
result suggests that B cells and particularly CD8+CD28−
T cells (because of their relatively short baseline telomere
length) might be more vulnerable to factors that cause
telomere shortening.
Our results are consistent with the recent finding by Lin
et al. of the rate of telomere changes being distinct for T cells,
B cells, and monocytes in any given subject [26]. Notably,
our results differ from a recent report by Daniali et al. that
telomeres shorten at the same rate in leukocytes, skin, fat, and
muscle tissues in a cohort of 87 subjects [39]. The different
results from our longitudinal study and Daniali’s study may
be because their study was based on a cross-sectional study
design and, in addition, the cell types examined in Daniali’s
and our studies are different.
Cross-sectional studies reported telomere length shorten-
ing of 15–19 bps in B cells [40, 41]. To our knowledge, ours
is the first study that reported longitudinal changes of TL in
B cells in vivo. The 196 bp/year telomere length change in
B cells in our study is much larger than the cross-sectional
reports. Onemain difference is that half of the participants in
this study are caregivers of autistic children, with high levels
of perceived stress. Our previous work and those of others
have shown that high psychological stress is associated with
shorter telomere length. It is possible that the overall high
attrition rate seen in B cells in this study is at least partially
due to the presence of these high stress participants.
3.4. Telomerase Activity at Baseline Does Not Predict Telomere
Length Change at 18 Months. Telomere length is under
multiple and complex controls. We determined whether
6 Journal of Immunology Research
Table 4: Correlation of telomere length change among different cell types (with correction for regression-to-the-mean (RTM)).
𝑟 (Pearson) ΔB ΔCD8+CD28− ΔCD8+CD28+ ΔCD4+ ΔPBMC
ΔB — 0.12 0.30 0.27 0.39∗
ΔCD8+CD28− — 0.55∗∗∗ 0.46∗∗ 0.34∗
ΔCD8+CD28+ — 0.65∗∗∗ 0.43∗∗
ΔCD4+ — 0.50∗∗∗
∗∗∗
𝑝 < 0.001.
∗∗
𝑝 < 0.01.
∗
𝑝 < 0.05.
T/S ratios were natural log-transformed and adjusted for age.
Table 5: Telomere length change in different cell types.
Cell type ΔTL(T/S ratio) StdDev
ΔB
−0.067
0.086
ΔCD8+CD28−
−0.056
0.109
ΔCD8+CD28+ 0.000 0.108
ΔCD4+
−0.016
0.086
ΔPBMC
−0.007
0.130
Mean TL change and comparisons are calculated from RTM-adjusted data.
T/S ratios from baseline and 18 months were natural log-transformed.
Table 6: Comparison of telomere length change in different cell
types (adjusted 𝑝 values).
Comparison 𝑝(unadjusted)
𝑝 (RTM-
adjusted)
B versus CD8+CD28− 0.6201 0.5998
B versus CD8+CD28+ 0.0034 0.0008
B versus CD4+ 0.0085 0.0038
B versus PBMC 0.013 0.0042
CD8+CD28− versus CD8+CD28+ 0.0068 0.0013
CD8+CD28− versus CD4+ 0.0251 0.0185
CD8+CD28− versus PBMC 0.048 0.0299
CD8+CD28+ versus CD4+ 0.2986 0.2264
CD8+CD28+ versus PBMC 0.7834 0.7297
CD4+ versus PBMC 0.6568 0.6133
T/S ratio changes from baseline to 18 months were natural log-transformed
and paired samples tests were performed. False discovery rate adjusted 𝑝
value of <0.005 is considered significant.
baseline telomerase enzymatic activity level, as measured
in cell extracts, predicted change in telomere length during
the subsequent 18-month period. Such telomerase activity
wasmeasured in unstimulated PBMCs, CD4+, CD8+CD28+,
and CD8+CD28− T cells and B cells at baseline. Repli-
cating our earlier findings, we found that, in this cohort,
within an individual, first, each cell subtype fraction has a
characteristic mean telomerase activity level (Figure 2 and
Table S1). Comparison of telomerase activity of this cohort
to the postmenopausal women cohort [19] shows overall
higher telomerase activity levels, consistent with this cohort’s
younger age. Also, consistent with our earlier results [19],
cross-sectionally, there was no correlation between telom-
ere length and telomerase activity within each cell type.
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Figure 2: Box and whisker plots display interquartile range, median
values, andmaximum andminimumvalues of telomerase activity in
B cells, CD4+, CD8+CD28+, and CD8+CD28− T cells, and PBMCs.
Extending our earlier cross-sectional results, the present
longitudinal data show that telomerase activity at baseline
does not predict telomere length change after 18 months.
Our results are different from those of Lin et al. [26]
where telomere attrition in T cells with age was explained by a
decline in telomerase activity in a cohort of 216 subjects aged
20–90 years [26]. One possible explanation for the difference
between our results and theirs may be due to the narrow
age range of our cohort (20 to 50 years old) when compared
to theirs. Additionally, our study may be underpowered to
detect small effect sizes due to small sample size. Specifically,
since CD8+CD28− cells constitute a very small percentage
of the total PBMCs, we were only able to obtain enough
CD8+CD28− T cells for both telomere length and telomerase
activity assays in 11 out of the 39 subjects.
The correlation of TL change in various immune cell
types is indicative of underlying common factors, mecha-
nisms, and pathways that contribute to the observed changes.
Telomerase, due to its ability to extend telomere length,
is proposed to be one such factor. Forced experimental
overexpression of telomerase in numerous systems extends
telomere length [42]. There are also ample examples during
development and disease progression in which telomerase
is naturally upregulated, for instance, in B cells in the
germinal center, a site where B cells proliferate and mature.
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This upregulation of telomerase activity is accompanied by
telomere length increase [43]. Although logically one would
expect telomerase at one point to predict change in telomere
length, this had never been tested in normal cells in humans
longitudinally. Unlike the results reported by Lin et al.
[26], we did not observe predictive relationships between
telomerase at baseline and telomere shortening. There could
be several reasons why this is the case. Telomerase is under
many tight controls, including elaborate cis-regulation of
telomerase elongation on telomeric DNA by proteins at
the telomeres themselves. Hence, in our cohort and in the
cell types examined, many factors other than the measured
telomerase activity level may be the predominant forces
that determine telomere length change. Secondly, telomerase
activity is upregulated in immune cells in response to antigen
or mitogen stimulation [44], but wemeasured the telomerase
activity in unstimulated PBMC and sorted cells. It is likely
that telomerase activity in stimulated cells is more influential
to telomere length change. We note that while we had
examined whether telomerase activity at the baseline visit in
PBMC, CD4+, CD8+CD28+, and CD8+CD28− T cells and
B cells predicted telomere length change in the respective
cell types and did not find any association, it is possible
that in other cell types telomerase activity is more predictive
of telomere length change. For example, as in patients with
rare Mendelian telomerase mutations that reduce telomerase
activity by half and cause very short telomeres, in the general
population, telomerase activity in hematopoietic progenitor
cells at the baseline visit would likely be associated with
telomere length in the differentiated cells. However, we could
not measure the progenitor cells in this study. Finally, it is
possible that our study is underpowered to detect associations
due to small sample size.
4. Conclusions
Circulating immune cells are a mixture of many cell types
mainly including T and B cells, within which are various
populations of subsets that are developmentally related to one
another with shared, yet distinctive, signaling pathways. As
these cells are exposed to the same biochemical factors in
circulation that impact telomere length change, the rate of
telomere length change therefore is the result of cell type-
specific intracellular responses to these common external
factors.
We show in this study that telomere length changes
in CD4+, CD8+CD28+, and CD8+CD28− T cells and B
cells from the same participant are correlated, suggesting
systematic responses to biochemical factors that impact
telomere length. Yet, the rates of telomere length change differ
for different immune cell types, indicating cell type-specific
responses. Further studies are needed to discover what these
factors are, how they exert cell type-specific influences on
telomere length change, and how the relationship between
these factors and telomere length contributes to disease and
risks. These discoveries could have implications for how
we understand changes in mixed cell groups. Most studies
examine whole blood telomere length and some examine
PBMC telomere length. Few studies we are aware of have
examined CD8+CD28− change over time, probably because
of the expense and effort required. Whole blood consists of
a very high percentage of granulocytes, so any greater rate
of attrition in presenescent cells (CD8+CD28−) will likely
have little influence on the average change in TL. While
PBMC telomere length change may be a more sensitive
marker of replicative senescence for CD8+ T cells than whole
blood, the correlations suggest that CD8+CD28− cells are not
showing any greater influence than other cell types on the
PBMC change value, which is not surprising given that the
CD8+CD28− T cells constitute only a very small percentage
of the total PBMCs.
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